ACAD Stock Clocks Worst Day In 2 Years After Alzheimer’s Psychosis Drug Misses Main Goal — Citi Cuts Drug’s Success Odds To 20%

Shares of Acadia Pharmaceuticals (ACAD) clocked their worst day since August 2024 on Thursday after remlifanserin, its experimental treatment for hallucinations and delusions in Alzheimer’s disease psychosis, missed the primary endpoint of a mid-stage study.Shares closed down 13% from Wednesday’s c…